REGENXBIO INC

RGNXNASDAQ

🏆 #2996 by market capEarnings Nov 4 · PostUS Equity

$7.44▼ $0.04 (−0.60%)

After hours · at close

🔔

Track RGNX

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.6%

7d▼ 8.8%

14d▼ 6.4%

30d▼ 23.2%

ytd▼ 48.5%

1y▼ 24.6%

🏦Market Cap

$471M

Small Cap

📈Revenue Growth (YoY)

+12.0%

Healthy

📊Gross Margin

86.4%

High

💵FCF Margin

18.7%

Healthy

⚖️P/S Ratio

2.8x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $7.37 – $7.53
52-Week Range: $5.46 – $16.19
Volume: $1.94B
Avg Volume: $2.42B
Shares Outstanding: 63.3M
Next Earnings: Dec 8, 2026

Fundamentals Snapshot

Annual Revenue: $170M
Last Q Revenue: $108M
P/E Ratio: —
P/S Ratio: 2.8x
EPS (TTM): $-3.79
Dividend Yield: —
Dilution (1yr): +1.7%

Why Investors Own RGNX

✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

REGENXBIO INC

RGNX

Financial Trends

Revenue

$170M▲ +104.5% YoY

Gross Margin

88.1%▲ +47.5% YoY

Operating Income

−$161M▼ −30.9% YoY

Free Cash Flow

−$126M▼ −28.0% YoY

Shares Outstanding

51.8M▲ +1.7% YoY

Net Cash

−$226M▼ −$202M YoY

StockOtter · stockotter.space

About REGENXBIO INC

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.

🦦